Dilated cardiomyopathy: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• DMD 0
• SGLT2 0
• TP53 0
• IL-1 1
• IL-17 0
• NRF2 0
• PI3K 0
• PPAR 0
• CD40 0
• ERK 0
• GLP-1 0
• IL-6 0
• MAPK 0
• mTOR 0
• NLRP3 0
• PD-1 0
• PDE4 0
• PINK1 0
• RUNX1 0
• STAT3 0
• STING 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R21

  Failure to resolve an adaptive stress state contributes to Duchenne Muscular Dystrophy Severity

  University of Southern California· Los Angeles, United States· US$211,650 awarded in fiscal year 2026· until Aug 2028

• NIH NIA · R44

  IND-enabling program for novel stimulant FBD-400

  Firebird Pharmaceuticals, Inc.· Boston, United States· US$1,654,275 awarded in fiscal year 2026· until May 2028

• NIH NINDS · R56

  Treg-mediated tolerance of dystrophin immunity

  University of California-Irvine· Irvine, United States· US$549,500 awarded in fiscal year 2026· until Aug 2027

• NIH NIAMS · R01

  Targeting protein N-terminal methyltransferase in muscle diseases

  Purdue University· West Lafayette, United States· US$587,757 awarded in fiscal year 2026· until Jun 2031

• NIH NIAMS · R21

  Lipin1 and Micro-Dystrophin Gene Therapies for DMD: Independent and Combined Therapeutic Potential

  Wright State University· Dayton, United States· US$377,077 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  From n=1 to many: Scaling-up gene editing for future heart therapies (ONE2MANY)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,499,468· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Arrhythmogenesis in Dilated Cardiomyopathy: Role of Mechano-Electric Coupling (RhythMEC)

  Albert-Ludwigs-Universitaet Freiburg· Freiburg, Germany· EU contribution €265,648· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions (CARDIOREPAIR)

  European Molecular Biology Laboratory· Heidelberg, Germany· EU contribution €4,617,351· until Sept 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-EIC

  Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families. (DCM-NEXT)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €4,137,669· until Sept 2027· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Beyond the chromosome: unravelling the interplay between inter-chromosomal genome architecture and mRNA biogenesis (TRANS-3)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €1,769,998· until Aug 2028

10 of 275 running projects, newest first. Listed amounts together: US$147.8m + €14.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 1
• Mendelian Randomization Analysis 8
• CRISPR-Cas Systems 2
• Gene Expression Profiling 23
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 11
• Proteomics 9
• Metabolomics 3
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 20
• Machine Learning 8
• Deep Learning 2
• Cohort Studies 15
• Genome-Wide Association Study 11

• Shared Genetic Architecture Between Mental Disorders and Heart Failure Subtypes: A Comprehensive Multitrait Genome-Wide Analysis.

  J Am Heart Assoc, Oct 2026

• Whole-genome sequencing identifies a c.1282C > T missense variant in Taurine Transporter (TauT) associated with taurine-mediated dilated cardiomyopathy in a family of domestic shorthair cats.

  J Mol Cell Cardiol, Sept 2026

• The bidirectional genetic causality between immunocyte phenotypes and dilated cardiomyopathy: A bidirectional Mendelian randomization study.

  Medicine (Baltimore), Jul 2026

• Integrative Observational and Genetic Evidence From the UK Biobank Supports Carotid Intima-Media Thickness as a Window Into Cardiac Remodeling.

  J Am Heart Assoc, Jul 2026

• Engineered Heart Tissues Facilitate Noncoding Variant Studies in Cardiomyopathy.

  Circ Res, Jun 2026

• Antibody-mediated immune responses and cardiovascular disease: a Mendelian randomization study.

  Exp Biol Med (Maywood), May 2026

• Mendelian randomization and transcriptome analysis reveal depression-driven regulatory patterns of the immune microenvironment in myocardial infarction and heart failure.

  Front Immunol, Jan 2026

• Potential Risk Factors and Therapeutic Targets for Dilated Cardiomyopathy Identified Through Mendelian Randomization Analysis.

  J Am Heart Assoc, Dec 2025

• Systolic and diastolic blood pressure, abdominal obesity, and alcohol consumption contribute to the risk of hypertrophic and dilated cardiomyopathies in European and East Asian populations.

  BMC Med, Dec 2025

• The Utility of Genome-Wide Association Studies in Inherited Arrhythmias and Cardiomyopathies.

  Genes (Basel), Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.